Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Jacob Stultz, Lawrence Fong
Prostate Cancer and Prostatic Diseases (2021) Vol. 24, Iss. 3, pp. 697-717
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy
He Wang, Zhiyuan Gao, Di Jiao, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 16
Closed Access | Times Cited: 51
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 45
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
Neeraj Agarwal, Bradley A. McGregor, Benjamin L. Maughan, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 7, pp. 899-909
Closed Access | Times Cited: 44
Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes
Dingyi Wang, Zhuo Wan, Qian Yang, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 702-713
Open Access | Times Cited: 43
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Xuhui Bao, Liyi Xie
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 42
Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance
Martina Bedeschi, Noemi Marino, Elena Cavassi, et al.
Cells (2023) Vol. 12, Iss. 5, pp. 802-802
Open Access | Times Cited: 32
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Emerson A. Lim, Michael T. Schweizer, Kim N., et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 3, pp. 366-375
Open Access | Times Cited: 29
Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer
Yao Sun, Michael F. Cronin, Monique Culturato Padilha Mendonça, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 185, pp. 106427-106427
Open Access | Times Cited: 27
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
Jessica E. Hawley, Aleksandar Z. Obradovic, Matthew C. Dallos, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1972-1988.e5
Open Access | Times Cited: 26
Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis
Justin K. Messex, Geou‐Yarh Liou
Life (2023) Vol. 13, Iss. 2, pp. 333-333
Open Access | Times Cited: 24
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
Meghana S. Pagadala, Timothy J. Sears, Victoria H. Wu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
The potential role of the microbiota in prostate cancer pathogenesis and treatment
Nicolò Pernigoni, Christina Guo, Lewis Gallagher, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 12, pp. 706-718
Closed Access | Times Cited: 22
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Atish D. Choudhury, Lucia Kwak, Alexander Cheung, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 6, pp. 704-718
Open Access | Times Cited: 13
Distinct mesenchymal cell states mediate prostate cancer progression
Hubert Pakula, Mohamed Omar, Ryan Carelli, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Activated aggregation‐induced emission therapeutics agents for triggering regulated cell death
Yu‐Qiang Zhao, Le Yu, Lanyun Zhang, et al.
Aggregate (2024) Vol. 5, Iss. 3
Open Access | Times Cited: 10
Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot
Yiman Han, Xin Tian, Jiaqi Zhai, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 9
The Current Therapeutic Landscape for Metastatic Prostate Cancer
A. Gómez Bernal, Alivia Bechler, Kabhilan Mohan, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 351-351
Open Access | Times Cited: 8
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3200-3210
Closed Access | Times Cited: 8
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Hongtao Song, Tong Lü, Donghui Han, et al.
Cancer Research (2024) Vol. 84, Iss. 22, pp. 3728-3742
Open Access | Times Cited: 8
Prostate cancer epigenetics — from pathophysiology to clinical application
Vera Constâncio, João Lobo, José Pedro Sequeira, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression
Mohamed A. Abu el Maaty, Julie Terzic, Céline Keime, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 36
Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer
Jasmine S. Owen, Aled Clayton, Helen Pearson
Biomolecules (2022) Vol. 13, Iss. 1, pp. 67-67
Open Access | Times Cited: 29
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Anthony W. Tolcher, Michael S. Gordon, Kathleen M. Mahoney, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e005267-e005267
Open Access | Times Cited: 17
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
Carlo Sorrentino, Emma Di Carlo
Cancers (2023) Vol. 15, Iss. 11, pp. 2885-2885
Open Access | Times Cited: 17
Interferon stimulated gene 15 (ISG15) in cancer: An update
Hong-My Nguyen, Shreyas Gaikwad, Mariam Oladejo, et al.
Cancer Letters (2023) Vol. 556, pp. 216080-216080
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top